Recent Updates
Recently added Catalysts

navenibart

Phase 3

Hereditary Angioedema (HAE) | Small molecule | Other |Astria Therapeutics, Inc.|Last Updated: Jun 5, 2026

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials2
Total Enrollment290
FDA Designations
No designations recorded
Clinical trial landscape

navenibart · 3 trials · 2 indications

Phase 3 2Phase 1 1
NCT07204938A Long-Term Study of Navenibart in Participants With Hereditary AngioedemaHereditary Angioedema (HAE)
ENROLLING BY_INVITATION145 Analytics
NCT06842823A Study of Navenibart in Participants With Hereditary AngioedemaHereditary Angioedema (HAE)
ENROLLING BY_INVITATION145 Analytics
PHASE3ENROLLING BY_INVITATION
A Long-Term Study of Navenibart in Participants With Hereditary Angioedema
Hereditary Angioedema (HAE)Unlock trial analytics
PHASE3ENROLLING BY_INVITATION
A Study of Navenibart in Participants With Hereditary Angioedema
Hereditary Angioedema (HAE)Unlock trial analytics
Study Endpoints
Primary Endpoints
Incidence of treatment-emergent adverse events (TEAEs)
Day 1 through Month 48
Number of time-normalized investigator-confirmed HAE attacks during the 6-month Treatment Period.
Day 1 through Day 181
Number of Participants Experiencing Treatment-emergent Adverse Events
Day 1 through Day 448 (Cohort 1), Day 531 (Cohort 2), Day 475 (Cohort 3)

An adverse event was any untoward medical occurrence in a clinical investigation participant who was administered a pharmaceutical product that did not necessarily have a causal relationship with the treatment. A treatment-emergent adverse event was defined as any adverse event with an onset at the time of or following the start of treatment with study drug, or medical conditions present before the start of treatment that increased in severity or relationship at the time of or following the start of treatment. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' section.

Secondary Endpoints
Number of time-normalized investigator-confirmed HAE attacks
Day 1 through Month 48
Number of moderate or severe investigator-confirmed HAE attacks
Day 1 through Month 48
Number of investigator-confirmed HAE attacks that require on-demand treatment
Day 1 through Month 48
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelPARALLEL
PurposePREVENTION
Treatment Arms
ArmTypeDescription
Adult Dosing Regimen 1EXPERIMENTALParticipants will receive 600 mg of navenibart every 3 months.
Adult Dosing Regimen 2EXPERIMENTALParticipants will receive 300 mg of navenibart every 3 months.
Adult Dosing Regimen 3EXPERIMENTALParticipants will receive 600 mg of navenibart every 6 months.
Adolescent Dosing Regimen 1EXPERIMENTALParticipants will receive 300 mg of navenibart every 3 months.
Adult Navenibart Dosing Regimen 1EXPERIMENTALParticipants will receive 600 mg of navenibart every 3 months.
Adult Navenibart Dosing Regimen 2EXPERIMENTALParticipants will receive 600 mg of navenibart on Day 1 and 300 mg every 3 months starting at month 3.
Adult Navenibart Dosing Regimen 3EXPERIMENTALParticipants will receive 600 mg of navenibart every 6 months.
Placebo (adult)PLACEBO_COMPARATORParticipants will receive placebo every 3 months.
Adolescent Navenibart Dosing Regimen 1EXPERIMENTALParticipants will receive 600 mg of navenibart on Day 1 and 300 mg every 3 months starting at month 3.
Cohort 1 - Single DoseEXPERIMENTALParticipants received 1 dose (450 milligrams \[mg\]) of navenibart.
Cohort 2 - Multiple DoseEXPERIMENTALParticipants received 2 doses (600 mg, 300 mg) of navenibart administered 3 months apart.
Cohort 3 - Multiple DoseEXPERIMENTALParticipants received 2 doses (600 mg) of navenibart administered 1 month apart.
Interventions
NameTypeDescription
navenibartDRUGNavenibart will be administered as a subcutaneous injection.
PlaceboDRUGPlacebo will be administered as a subcutaneous injection.
Unlock Study Design Details
Eligibility Criteria
Age Range12 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites28

Inclusion Criteria: 1\. Participants from STAR-0215-301 who met one of the following conditions: 1. Completed STAR-0215-301 through the Day 181 visit 2. Withdrew from STAR-0215-301 but met the following criteria: i. Received 2 doses of IP ii. completed ≥ 2 months of trial follow-up after the seco...

Countries:United StatesBrazilBulgariaCanadaGermanyHong KongIsraelJapanNetherlandsNorth MacedoniaPolandSouth AfricaSpainUnited KingdomAustraliaAustriaCzechiaFranceHungaryItalyNew ZealandPortugalPuerto RicoSouth Korea
Unlock Eligibility Criteria
Competitive Landscape -Hereditary Angioedema 9 trials (matched to "Hereditary Angioedema (HAE)")
Recent Changes (Last 90 Days)
MEDIUMJun 8, 2026NCT05695248TRIAL_REMOVED: changed
MEDIUMJun 8, 2026NCT05695248TRIAL_REMOVED: changed
MEDIUMJun 8, 2026NCT05695248TRIAL_REMOVED: changed
MEDIUMJun 8, 2026NCT05695248TRIAL_REMOVED: changed
MEDIUMJun 8, 2026NCT05695248TRIAL_REMOVED: changed
LOWJun 5, 2026NCT06842823Status: RECRUITING → ENROLLING_BY_INVITATION
LOWJun 5, 2026NCT06842823Status: RECRUITING → ENROLLING_BY_INVITATION
LOWJun 5, 2026NCT06842823Status: RECRUITING → ENROLLING_BY_INVITATION
LOWJun 5, 2026NCT06842823Status: RECRUITING → ENROLLING_BY_INVITATION
LOWJun 2, 2026NCT07204938lastUpdatePostDate: changed
LOWJun 2, 2026NCT07204938lastUpdatePostDate: changed
LOWJun 2, 2026NCT07204938lastUpdatePostDate: changed
LOWMay 26, 2026NCT06842823primaryCompletionDate: changed
LOWMay 26, 2026NCT07204938primaryCompletionDate: changed
LOWMay 24, 2026NCT06842823studyFirstPostDate: changed
LOWMay 24, 2026NCT07204938studyFirstPostDate: changed